What is DNTH's market cap?

$4.80B, based on the Nov 4 close of $85.81.

Does Dianthus Therapeutics pay a dividend?

No regular cash dividend has been paid in the last year.

How much of DNTH is sold short?

9.0M shares, 18.4% of float, as of Oct 15, 2026.

What sector is DNTH in?

Healthcare, in the Pharmaceuticals industry.

NASDAQ · DNTHHealthcarePharmaceuticals

Dianthus Therapeutics, Inc. Common Stock (DNTH)

$85.81+3.76%

Close Nov 4, 2026 · split-adjusted

Nov 4, 2026$85.81▲ 158.46% in range

Nov 4, 2025Low $33.20 · High $115.96Nov 4, 2026

What changed · written from our data

As of Nov 4, 2026

Dianthus Therapeutics closed at $85.81 on Nov 4, up 3.76%, 26.0% below its 52-week closing high. Volume of 1.7M shares was 1.77× its 20-day average (above normal).

Split-adjusted performance: +0.5% over one month, -5.1% over six months, +152.2% over one year.

In the quarter ended Jun 30, 2026, revenue was $761K, up 294.3% from a year earlier, with a net margin of -6598.6%.

Short interest was 9.0M shares at the Oct 15 settlement, down 1.7% from the prior report (18.4% of float, 10.2 days to cover).

Market cap$4.80B55.9M shares

Revenue · quarter$761.0K+294.3% YoY

Diluted EPS$-0.90—

P/E · TTM—P/S 2,520.9×

Net margin-6,598.6%Gross 100.0%

Dividend yieldNone

52-week range33.20 – 115.96−26.0% from high

Volume1.7M1.77× 20-day avg

Volatility · 60d38.9%Annualised

Short % of float18.4%10.2 days to cover

Net cash$886.8MCash $886.8M

Next earnings—Not scheduled

Split-adjusted performance

1W +4.3%1M +0.5%3M −21.9%6M −5.1%YTD +108.2%1Y +152.2%3Y +616.9%5Y —

Earnings reactions

History →

No reported quarters with price history yet.

Rank within Pharmaceuticals

Percentile among 420 companies (100 = best)

6-month momentum68

Revenue growth92

Net margin7

Value (low P/E)—

Size90

Industry medians: 6-month return −25.5%, revenue growth +6.2%, net margin −33.8%, P/E 16.1×.

Short interest

Details →

Shares short9.0M−1.7% vs prior

Days to cover10.2Settled Oct 15

% of float18.4%

Short vol. 10d52.8%of daily volume

Closest peers by size in Pharmaceuticals

Company	Price	Today	6M	Rev. growth	Net margin	P/E	Mkt cap
DNTHDianthus Therapeutics	$85.81	+3.76%	−5.1%	+294.3%	−6598.6%	—	$4.80B
TVTXTravere Therapeutics	$52.42	+6.09%	+17.1%	+36.2%	−23.3%	—	$4.94B	Compare
ERASErasca	$14.91	+1.84%	+36.8%	—	—	—	$5.21B	Compare
DFTXDefinium Therapeutics	$32.70	−2.13%	+39.6%	—	—	—	$4.39B	Compare
ARQTArcutis Biotherapeutics	$34.05	+6.41%	+40.9%	+59.3%	11.6%	150.1	$4.28B	Compare
LQDALiquidia	$47.38	+12.27%	+12.4%	+1842.7%	43.5%	30.6	$4.24B	Compare
COGTCogent Biosciences	$31.49	+1.38%	−12.2%	—	—	—	$5.46B	Compare
EWTXEdgewise Therapeutics	$37.53	−0.40%	+1.5%	—	—	—	$4.08B	Compare
MANEVeradermics, Incorporated	$136.51	+2.17%	+24.4%	—	—	—	$5.70B	Compare

News about Dianthus Therapeutics

All news →

Dianthus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswire Inc. · 2d agoNeutral Why This Fund Just Made a $55 Million Bet on Dianthus Amid a 350% Stock RallyThe Motley Fool · May 17, 2026▲ Positive LBL-047 Prioritized for Clinical Development in Sjögren's Disease, Systemic Lupus Erythematosus, and DermatomyositisGlobeNewswire Inc. · May 6, 2026▲ Positive Dianthus Therapeutics' (DNTH) CFO Sold 8,224 Shares for $739,000The Motley Fool · Apr 19, 2026Neutral Dianthus Therapeutics CFO Sells $9.5 Million in StockThe Motley Fool · Apr 6, 2026Neutral

Quick answers

What does Dianthus Therapeutics do?: Dianthus Therapeutics Inc. is a clinical-stage biotechnology company dedicated to developing potentially best-in-class therapies for patients with severe autoimmune diseases.
What is DNTH's market cap?: $4.80B, based on the Nov 4 close of $85.81.
Does Dianthus Therapeutics pay a dividend?: No regular cash dividend has been paid in the last year.
How much of DNTH is sold short?: 9.0M shares, 18.4% of float, as of Oct 15, 2026.
What sector is DNTH in?: Healthcare, in the Pharmaceuticals industry.

About Dianthus Therapeutics

Dianthus Therapeutics Inc. is a clinical-stage biotechnology company dedicated to developing potentially best-in-class therapies for patients with severe autoimmune diseases. The company operates as a single segment and has one reportable segment, focusing on creating next-generation treatments to revolutionize the management of severe autoimmune conditions. The team comprises experienced biotech and pharma executives. The pipeline includes the potential of Claseprubart, a next-generation complement therapeutic.

HQ: New York, NY92 employeesListed Sep 12, 2023dianthustx.com

Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology